Table 5.
Examples of completed clinical trials using different types of nanosystems for melanoma treatment.
| Nanosystem | Main Clinical Trial Description | Melanoma Stage | Sponsor | Starting and Completion Date | Trial ID |
|---|---|---|---|---|---|
| Liposomes | Safety, efficacy and pharmacokinetic profile study of vincristine sulfate liposomes (Phase 1). | III/IV | Acrotech Biopharma LLC | 2005–2007 | NCT00145041 |
| Safety and immunogenicity of a dendritic cells targeted-liposomal vaccine (Phase 1). | IV | Lipotek Pty Ltd. | 2009–2012 | NCT01052142 | |
| Polymeric nanoparticles | Safety and efficacy of nanoparticle albumin-bound paclitaxel (Phase 2). | Unresectable or metastatic | Jonsson Comprehensive Cancer Center | 2004–2010 | NCT00081042 |
| Safety and efficacy of the combination of nanoparticle albumin-bound paclitaxel with carboplatin (Phase 2). | IV | Alliance for Clinical Trials in Oncology | 2006–2010 | NCT00404235 | |
| Safety and efficacy of the combination of nanoparticle albumin-bound paclitaxel with avastin (Phase 2). | III/IV | Lynn E. Spitler, MD | 2007–2012 | NCT00462423 | |
| Comparison of the safety and efficacy of the combination of bevacizumab, carboplatin and nanoparticle albumin-bound paclitaxel with the combination of bevacizumab and temozolomide (Phase 2). | IV | Alliance for Clinical Trials in Oncology | 2008–2012 | NCT00626405 | |
| Comparison of the safety and efficacy of nanoparticle albumin-bound paclitaxel versus dacarbazine (Phase 3). | IV | Celgene | 2009–2014 | NCT00864253 | |
| Safety and pharmacokinetic and pharmacodynamic profile of PSMA-targeted PLA/PEG docetaxel nanoparticles (Phase 1). | Advanced or metastatic | BIND Therapeutics | 2011–2016 | NCT01300533 | |
| Comparison of the safety and efficacy of the combination of nanoparticle albumin-bound paclitaxel with bevacizumab versus ipilimumab alone (Phase 2). | IV | Academic and Community Cancer Research United | 2013–2019 | NCT02158520 |
Abbreviations: PEG: polyethylene glycol; PLA: polylactic acid; PSMA: prostate-specific membrane antigen. Data collected from the ClinicalTrials.gov database [126].